Ovarian cancer
Open
Other
This study is looking at tissue and blood samples to work out who benefits most from having a PARP inhibitor.
The study is for women who have:
ovarian cancer
primary peritoneal cancer
fallopian tube cancer
These cancers are treated in the same way. So when we use the term ovarian cancer in this summary, we are referring to all 3.
Recruitment start: 26 July 2022
Recruitment end: 31 January 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Patricia Roxburgh
Artios Pharma Limited
NHS Greater Glasgow and Clyde
Wellbeing of Women
Last reviewed: 16 July 2025
CRUK internal database number: 18446
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
